Table 1.
Medical and surgical information for patients undergoing left ventricular assist device (LVAD) insertion or coronary artery bypass graft (CABG) surgery
| Variable | LVAD Patients (n=15) | CABG Patients (n=10) | p Value LVAD vs. CABG |
|---|---|---|---|
| Age (years) (mean±SD) | 60±10 | 62±10 | 0.8784 |
| Gender | 0.085 | ||
| Male | 10 (67%) | 10 (100%) | |
| Female | 5 (33%) | 0 | |
| Hypertension | 7 (47%) | 8 (80%) | 0.211 |
| Diabetes | 6 (40%) | 6 (60%) | 0.428 |
| Chronic obstructive pulmonary disease | 4 (27%) | 1 (10%) | 0.615 |
| Peripheral vascular disease | 0 | 2 (20%) | 0.150 |
| Current tobacco smoker | 1 (7%) | 1 (10%) | 1.0 |
| Congestive heart failure | 15 (100%) | 2 (20%) | <0.0001 |
| Prior myocardial infarction | 0 | 1 (10%) | 0.400 |
| Prior stroke | 1 (7%) | 0 | 1.0 |
| Left carotid stenosis | 0.559 | ||
| 50–70% | 11 (73%) | 5 (50%) | |
| 70–90% | 1 (7%) | 1 (10%) | |
| >90% | 0 | 0 | |
| Right carotid stenosis | 0.378 | ||
| 50–70% | 12 (80%) | 6 (60%) | |
| 70–90% | 0 | 0 | |
| >90% | 0 | 0 | |
| Left ventricular ejection fraction <30% | 15 (100%) | 2 (20%) | <0.0001 |
| Medications | |||
| Aspirin | 7 (47%) | 9 (90%) | 0.040 |
| Beta-blockers | 7 (47%) | 3 (30%) | 0.678 |
| “Statin” drugs | 2 (13%) | 6 (60%) | 0.028 |
| Ca2+ channel blockers | 1 (7%) | 2 (20%) | 0.543 |
| ACE inhibitors | 4 (27%) | 4 (40%) | 0.667 |
| Dobutamine | 2 (13%) | 0 | 0.500 |
| Milrinone | 9 (60%) | 0 | 0.003 |
| Prior cardiac surgery | 4 (27%) | 1 (10%) | 0.615 |
| Cardiopulmonary bypass duration (min) | 79±33 | 89±24 | 0.4370 |
| Aortic cross-clamp duration (min) | - | 56±16 | |
| Epinephrine Infusion During | 10 | 1 | 0.014 |
| Postoperative Day 1 Monitoring |
Abbreviation: ACE, angiotensin-converting enzyme.